The EverLife Capital Brief · October 30, 2026
Something for the curious: if you enjoy learning how things work, A Little Wiser is a free newsletter built on one simple idea: three short lessons, three mornings a week, each about three minutes. Quick enough to read with your morning coffee, and easy to drop if it is not for you. Try A Little Wiser free →
Paid link: EverLife Capital earns a referral fee if you subscribe.
What's Moving From Lab To Humans For Brain And Memory Repair
Even a healthy brain shrinks with age: about 0.2% a year from age 35, rising to 0.5% a year or more after 60 (Human Brain Mapping review). And 7.4 million Americans 65 and older, about 1 in 9, live with Alzheimer's (Alzheimer's Association, 2026).
That makes brain repair one of the fields that matters most as we age, and one companies are racing to build. The treatments below target specific diseases; whether they help healthy aging is not yet known. Here is what is moving from the lab to people, and how strong the evidence really is.
Stay to the end: the most surprising result is the very last one.
💊 Approved Treatments
Lilly's Alzheimer's Drug Slowed Decline By 22% Overall, 35% In A Key Subgroup
In a 1,736-patient trial in early symptomatic Alzheimer's, Kisunla slowed decline on the main combined thinking-and-daily-function measure by 22% overall, and by 35% in patients with low-to-medium tau levels, versus placebo over about 18 months. It slows the disease; it does not stop or reverse it. ARIA-related brain swelling showed up on scans in 24% of patients, 6.1% had symptoms, and three deaths were attributed to ARIA. Kisunla sales reached $167M in Q2 2026, up from $49M a year earlier. Shown in: people. LLY: $1,373.00 and market cap about $1.29T (Oct 29 close); cash $8.95B (June 30, 2026).
A Leqembi Alzheimer's Shot Can Now Be Started At Home
In July 2026, the FDA approved Leqembi Iqlik as a weekly autoinjector that patients can use at home from the very first dose, instead of IV infusions at a clinic. In its 1,795-patient trial, Leqembi slowed decline by 27% at 18 months versus placebo. ARIA-related brain swelling showed up on scans in 12.6% of patients versus 1.7% on placebo. Shown in: people. BIIB: $249.65 and market cap about $36.9B (Oct 29 close); cash $1.29B (June 30, 2026). Eisai (4523.T), its partner: ¥4,974 [about $31.50] and market cap about ¥1.40T [about $8.9B] (Oct 29 close); cash ¥311.7B [about $2.0B] (June 30, 2026).
🧪 Repairing The Brain With New Cells, In People
Stem-Cell Neurons For Parkinson's Have Reached A Phase 3 Trial
BlueRock, owned by Bayer, implants dopamine neurons grown from stem cells to replace those lost in Parkinson's. In a 12-patient early trial with no comparison group, the high-dose group's movement scores improved by an average of 17.9 points at 3 years, with no therapy-related serious side effects. A roughly 102-patient Phase 3 against sham surgery began in September 2025. Shown in: people (12, no comparison group). BAYN: €47.96 [about $53.53] and market cap about €47.2B [about $52.6B] (Oct 29 close); cash €4.29B [about $4.8B] (June 30, 2026).
Parkinson's Patients' Own Skin Cells, Turned Into Brain Cells
Aspen Neuroscience reprograms each patient's own skin cells into dopamine neurons, so no immune-suppressing drugs are needed. In 8 patients with no comparison group, "good" daily hours without symptoms rose by about 2 at 12 months. Aspen says it plans to move to Phase 3 in 2026. Shown in: people (8, no comparison group). Private; raised a $115M Series C in November 2025.
Lab-Made Neurons Cut Epilepsy Seizures By 89% In A Small Group
Neurona implants calming neurons to stop drug-resistant seizures without removing brain tissue. In the 9 patients who got the low dose, disabling seizures fell by a median 89%, with no group decline in memory, which surgery for this condition can harm. UCB bought Neurona for up to $1.15B in 2026 and plans a controlled Phase 3 in the first half of 2027. Shown in: people (small, no comparison group). UCB: €280.00 [about $313] and market cap about €53.4B [about $59.6B] (Oct 29 close); cash €766M [about $856M] (June 30, 2026).
EverLife Capital Members
Look Beyond The Breakthrough Headlines
Members get plain-English analysis of each company we cover: who the results were shown in, and the warning signs to check before putting money in. You can also ask us to analyze the companies you care about. Free for 14 days.
Biotechnology investments can lose substantial value, including your entire investment. Clinical success or regulatory approval does not guarantee commercial success or investment returns.
🐒 Early Or In Animals
Clearing "Zombie" Cells From Aging Mouse Brains
In naturally aged mice, senolytic drugs cleared harmful senescent immune cells near the brain's memory center and restored a more youthful structure (Nature Aging, August 2026). Memory was not measured. Shown in: mice.
The U.S. Is Funding Efforts To Regrow Damaged Brain Tissue
ARPA-H's FRONT program picked Sophrosyne Biosciences in May 2026 to grow brain-tissue grafts from patients' own cells, aimed at stroke and injury. No results yet. Shown in: not yet tested.
🌟 Saved For Last: One Shot, Sharper Memory In Old Monkeys
One Shot Of A "Longevity Protein" Sharpened Memory In Old Monkeys
In 18 aged monkeys (about 65 in human years), one low-dose injection of klotho raised working-memory accuracy from about 45% to 60%, within 4 hours and lasting at least 2 weeks. Higher doses did not help. No human trial has been announced. Shown in: monkeys. Academic research (UC San Francisco).
Questions or ideas? Just hit reply.
Talk soon,
Eric
What Should We Investigate Next?
Want to advertise in EverLife Capital? Reach readers focused on aging well and longevity science. Email [email protected]. We do not accept payment, directly or through agencies, from companies we cover.
EverLife Capital publishes general educational research, not personalized investment or medical advice, and nothing here is a recommendation to buy or sell any security. EverLife Capital earns a referral fee when readers subscribe to A Little Wiser through this issue; no company covered in this issue paid for coverage, directly or indirectly. Early clinical findings and animal results may not lead to lasting benefits for patients, and clinical progress does not guarantee investment returns. Treatment decisions belong with a qualified clinician. Prices are dated where shown and may have changed. EverLife Capital is published by Consult US, LLC. Neither Eric Pemper nor Consult US, LLC holds positions in companies mentioned. Some research and summaries are prepared with AI assistance and reviewed before publication.
